Baidu
map

JASN:CKD患者肾脏功能下降斜率及其与死亡率和心血管疾病之间的关系

2020-10-12 MedSci原创 MedSci原创

在中度至重度CKD人群中,研究人员观察到eGFR的急剧下降与死亡和心血管事件的风险逐渐增加有关。但是,研究人员没有发现与eGFR改善相关的风险增加。

估计的肾小球滤过率(eGFR)下降斜率与升高的死亡和血管事件风险呈U形关系。eGFR升高的个体预后不良可能归因于肌肉减少症,血液稀释和其他临床恶化的指标。

近日,肾脏病领域权威杂志Journal of the American Society of Nephrology上发表一篇研究文章,该研究旨在探究eGFR斜率与死亡或心血管事件风险之间的关联,并考虑多种混杂因素。研究人员分析了2738名中度至重度CKD患者,并使用线性、混合效应模型评估了每年四次eGFR评估的斜率,而采用Cox比例风险模型评估斜率与死亡和心血管事件风险之间的关联。

eGFR斜率呈钟形分布(平均[SD]为每1.73 m2每年-1.5 [-2] ml/min)。eGFR下降幅度大于平均下降幅度,这与死亡(风险比[HR]为1.23;95%置信区间[95%CI]为1.09至1.39)和心血管事件(HR为1.19;95%CI为1.03至1.38)风险的逐步增加相关。eGFR的升高或下降低于平均下降水平与死亡或心血管事件的风险无关。

在中度至重度CKD人群中,研究人员观察到eGFR的急剧下降与死亡和心血管事件的风险逐渐增加有关。但是,研究人员没有发现与eGFR改善相关的风险增加。这些结果支持eGFR斜率在CKD患者临床评估中的潜在价值。

原始出处:

Paula F. Orlandi,et al.Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD.JASN,2020.https://jasn.asnjournals.org/content/early/2020/10/09/ASN.2020040476

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941384, encodeId=6b7119413849a, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Jul 22 14:19:16 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768853, encodeId=54621e6885363, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Thu Sep 16 22:19:16 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498781, encodeId=5f801498e8183, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 05:19:16 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891707, encodeId=4ea1891e07d0, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 13 09:45:25 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891522, encodeId=31d6891522f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 18:30:24 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2021-07-22 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941384, encodeId=6b7119413849a, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Jul 22 14:19:16 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768853, encodeId=54621e6885363, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Thu Sep 16 22:19:16 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498781, encodeId=5f801498e8183, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 05:19:16 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891707, encodeId=4ea1891e07d0, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 13 09:45:25 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891522, encodeId=31d6891522f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 18:30:24 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1941384, encodeId=6b7119413849a, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Jul 22 14:19:16 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768853, encodeId=54621e6885363, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Thu Sep 16 22:19:16 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498781, encodeId=5f801498e8183, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 05:19:16 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891707, encodeId=4ea1891e07d0, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 13 09:45:25 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891522, encodeId=31d6891522f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 18:30:24 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941384, encodeId=6b7119413849a, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Jul 22 14:19:16 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768853, encodeId=54621e6885363, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Thu Sep 16 22:19:16 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498781, encodeId=5f801498e8183, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 05:19:16 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891707, encodeId=4ea1891e07d0, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 13 09:45:25 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891522, encodeId=31d6891522f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 18:30:24 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2020-10-13 易水河

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1941384, encodeId=6b7119413849a, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Jul 22 14:19:16 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768853, encodeId=54621e6885363, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Thu Sep 16 22:19:16 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498781, encodeId=5f801498e8183, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 05:19:16 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891707, encodeId=4ea1891e07d0, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Oct 13 09:45:25 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891522, encodeId=31d6891522f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4325398811, createdName=ms4000002070088423, createdTime=Mon Oct 12 18:30:24 CST 2020, time=2020-10-12, status=1, ipAttribution=)]
    2020-10-12 ms4000002070088423

    学习

    0

相关资讯

Lancet:慢性肾病疾病负担研究——1990-2017

研究发现,全球范围内肾病负担仍十分沉重,是全球死亡及心血管死亡的重要因素

AJKD:儿童血浆suPAR与CKD进展

由此可见,suPAR水平越高,CKD儿童开始肾脏替代治疗或eGFR减半的时间越短。

JASN:收缩压纵向变化轨迹与CKD发生风险之间的关联

随着时间的推移,收缩压升高而未达到高血压阈值,则与健康成年人发生CKD的风险增加显著相关。

JASN:2型糖尿病患者AKI与CKD之间的关系

与没有糖尿病的患者相比,糖尿病患者的AKI发生率显著升高,并且对于CKD的患者仍然如此。

AJKD:周围动脉疾病:有或没有CKD的不良结局比较

由此可见,与eGFR≥60 mL/min/1.73m2的患者相比,CKD G3-G5和G5D患者中PAD更为常见,且经常导致下肢并发症。迫切需要专门设计用于减缓或预防该人群下肢并发症发生的医疗干预措施。

NEJM:晚期肾病的患者,出现中重度心肌缺血时,保守治疗还是侵入性治疗?

美国纽约大学格罗斯曼医学院Sripal Bangalore课题组的一项最新研究,探讨了晚期肾病患者冠状动脉疾病的管理策略。相关论文发表在2020年3月30日出版的《新英格兰医学杂志》上。

Baidu
map
Baidu
map
Baidu
map